- AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage psychedelic drug developer, is being acquired by Eli Lilly (NYSE: LLY).
- The acquisition deal is valued at an initial $2.8 billion (or $6.75 per share) with potential additional $1 billion via Contingent Value Rights (CVRs).
- Following the announcement, shares of ATAI surged 33.4% to $7.15, though Cowen & Co. downgraded the stock to “Hold” at $7.22.
AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage company that develops psychedelic drugs for mental health disorders. The company is currently in the process of being acquired by pharmaceutical giant Eli Lilly (NYSE: LLY). This move highlights a growing interest from large drug companies in the potential of psychedelic-based therapies for difficult-to-treat conditions.
Eli Lilly is acquiring ATAI for an initial payment of $2.8 billion, or $6.75 per share in cash. As highlighted by Zacks Investment Research, this acquisition aims to expand Eli Lilly’s portfolio of treatments for brain and nervous system disorders. The deal centers on ATAI’s promising pipeline of new therapies.
The agreement also includes potential future payments known as Contingent Value Rights (CVRs). These CVRs could add up to $2.50 per share, or about $1 billion total, if certain company goals are met. These goals often relate to the successful development and regulatory approval of new drugs in the pipeline.
Following the acquisition announcement, shares of ATAI increased by 33.4% to close at $7.15. The trading volume for the stock was 1,494% above its three-month average, showing significant investor interest. The stock’s price on July 17, 2026, is $7.22, which is near its new 52-week high.
On July 17, 2026, the firm Cowen & Co. issued a downgrade for ATAI, changing its rating from “Buy” to “Hold.” A “Hold” rating suggests that analysts believe the stock is fairly valued and has limited room for significant price growth. This change occurred when the stock price was $7.22.
